首页> 外文期刊>European journal of neurology: the official journal of the European Federation of Neurological Societies >A novel compound heterozygous dysferlin mutation in Miyoshi myopathy siblings responding to dantrolene.
【24h】

A novel compound heterozygous dysferlin mutation in Miyoshi myopathy siblings responding to dantrolene.

机译:响应dantrolene的三好肌病兄弟姐妹中的新型复合杂合dysferlin突变。

获取原文
获取原文并翻译 | 示例
           

摘要

Miyoshi myopathy (MM) is an autosomal recessive distal muscular dystrophy characterized by mutations of the dysferlin gene. Although several pairs of homozygous/heterozygous mutations have been reported, few effective treatments of MM are available. We had observed the decreased serum creatine kinase (CK) before and after administration of dantrolene in the elder brother and the increased serum CK before and after discontinuance of the drug on suspicion of drug-induced hepatopathy in the younger sister. We report a novel pair of heterozygous mutations in the 3'-splicing site of exon 26 and the translation site of exon 28 of the dysferlin gene in two siblings, and effective treatment of their MM with dantrolene.
机译:三好肌病(MM)是常染色体隐性遗传性远端肌营养不良症,其特征在于dysferlin基因的突变。尽管已经报道了几对纯合/杂合突变,但是很少有有效的MM治疗方法。我们已经观察到哥哥在服用丹特罗之前和之后的血清肌酸激酶(CK)降低,而在妹妹中因怀疑药物诱发的肝病而停药前后的血清CK增加。我们报告在两个同胞中的dysferlin基因外显子26的3'剪接位点和外显子28的翻译位点的一个新的一对杂合突变,并用丹特罗有效治疗他们的MM。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号